WO2011123683A3 - Protease activated cytokines - Google Patents

Protease activated cytokines Download PDF

Info

Publication number
WO2011123683A3
WO2011123683A3 PCT/US2011/030787 US2011030787W WO2011123683A3 WO 2011123683 A3 WO2011123683 A3 WO 2011123683A3 US 2011030787 W US2011030787 W US 2011030787W WO 2011123683 A3 WO2011123683 A3 WO 2011123683A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
protease activated
chimeric polypeptides
activated cytokines
cancer
Prior art date
Application number
PCT/US2011/030787
Other languages
French (fr)
Other versions
WO2011123683A2 (en
Inventor
John G. Frelinger
John Puskas
Baek Kim
Mark Sullivan
Original Assignee
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rochester filed Critical University Of Rochester
Priority to US13/639,006 priority Critical patent/US8734774B2/en
Priority to EP11763460.0A priority patent/EP2553101A4/en
Publication of WO2011123683A2 publication Critical patent/WO2011123683A2/en
Publication of WO2011123683A3 publication Critical patent/WO2011123683A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are chimeric nucleic acid sequences encoding chimeric polypeptides. Also provided herein are chimeric polypeptides. Further provided herein are methods of treating a subject with or at risk of developing a cancer. The methods comprise selecting a subject with or at risk of developing a cancer, and administering to the subject an effective amount of the chimeric polypeptides provided herein.
PCT/US2011/030787 2010-04-02 2011-03-31 Protease activated cytokines WO2011123683A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/639,006 US8734774B2 (en) 2010-04-02 2011-03-31 Protease activated cytokines
EP11763460.0A EP2553101A4 (en) 2010-04-02 2011-03-31 Protease activated cytokines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32036010P 2010-04-02 2010-04-02
US61/320,360 2010-04-02

Publications (2)

Publication Number Publication Date
WO2011123683A2 WO2011123683A2 (en) 2011-10-06
WO2011123683A3 true WO2011123683A3 (en) 2012-02-23

Family

ID=44712847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/030787 WO2011123683A2 (en) 2010-04-02 2011-03-31 Protease activated cytokines

Country Status (3)

Country Link
US (1) US8734774B2 (en)
EP (1) EP2553101A4 (en)
WO (1) WO2011123683A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052908T2 (en) 2012-06-08 2021-05-28 Alkermes Pharma Ireland Ltd Ligands modified by circular permutation as agonists and antagonists
EP3004154A4 (en) * 2013-06-05 2017-01-04 Ben Gurion University of The Negev Research and Development Authority IL-1beta-IL-1Ra CHIMERA AND METHODS OF USING THE SAME
MA40721A (en) * 2014-08-06 2017-06-13 The Univ Of Miami INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
JP7323102B2 (en) * 2016-04-13 2023-08-08 オリマブス リミテッド ANTI-PSMA ANTIBODY AND USES THEREOF
JP7178906B2 (en) * 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション Interleukin-2 tethered to its receptor IL-2Rβ, a platform for enhancing the activity of natural killer cells and regulatory T cells
KR20240018673A (en) 2016-11-28 2024-02-13 추가이 세이야쿠 가부시키가이샤 Antigen-binding domain, and polypeptide including conveying section
WO2019183389A1 (en) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
AR115024A1 (en) * 2018-03-28 2020-11-18 Bristol Myers Squibb Co INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 RECEPTOR a AND METHODS OF USE
MX2020012251A (en) * 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Activatable interleukin-2 polypeptides and methods of use thereof.
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
SG11202011309SA (en) * 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of use thereof
WO2019230868A1 (en) * 2018-05-30 2019-12-05 中外製薬株式会社 Ligand-binding molecule containing single domain antibody
CA3102823A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US20210163562A1 (en) * 2018-07-25 2021-06-03 AskGene Pharma, Inc. Novel IL-21 Prodrugs and Methods of Use Thereof
CN112867503A (en) * 2018-08-24 2021-05-28 希望之城 Masked cytokine conjugates
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
SG11202112541RA (en) * 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
CN113874390A (en) * 2019-05-24 2021-12-31 普罗维瓦疗法香港有限公司 IL-2 compositions and methods of use thereof
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
EP3997115A4 (en) * 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
US20220281936A1 (en) * 2019-07-25 2022-09-08 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
WO2021016599A1 (en) * 2019-07-25 2021-01-28 Trutino Biosciences Inc Il-2 cytokine prodrugs comprising a cleavable linker
JP2023503258A (en) * 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド Activatable cytokine polypeptides and methods of use thereof
WO2021113577A1 (en) * 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
TW202136317A (en) 2019-12-20 2021-10-01 美商再生元醫藥公司 Novel il2 agonists and methods of use thereof
KR20220128413A (en) * 2020-01-15 2022-09-20 트루티노 바이오사이언시스 인코포레이티드 Cytokine IL-2 prodrug comprising a cleavable linker
AU2021245922A1 (en) * 2020-04-01 2022-10-13 Xilio Development, Inc. Masked IL-2 cytokines and their cleavage products
US11365233B2 (en) 2020-04-10 2022-06-21 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2021222762A2 (en) 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Activatable il2 composition and methods of use
IL304959A (en) * 2021-02-09 2023-10-01 Univ Case Western Reserve Compositions and methods for targeted amplification of coagulation and phagocytosis
KR20230157448A (en) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. Masked activatable cytokine constructs and related compositions and methods
WO2023002952A1 (en) 2021-07-19 2023-01-26 Chugai Seiyaku Kabushiki Kaisha Protease-mediated target specific cytokine delivery using fusion polypeptide
WO2023121254A1 (en) * 2021-12-20 2023-06-29 한양대학교 산학협력단 Interleukin-2 fusion protein, method for preparing same, and pharmaceutical composition comprising same
CN115141283A (en) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 Fusion protein, preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151478A1 (en) * 2001-01-09 2002-10-17 Yuti Chernajovsky Latent fusion protein
US6670147B1 (en) * 1997-01-16 2003-12-30 Aventis Pharma Deutschland Gmbh Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
US20040033511A1 (en) * 2000-09-15 2004-02-19 Klaus Pfizenmaier Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines)
US20040259768A1 (en) * 2002-09-03 2004-12-23 Vit Lauermann Targeted release
US20050214762A1 (en) * 2002-01-25 2005-09-29 Asterion Limited Polypeptide variants
US20060205926A1 (en) * 2003-04-09 2006-09-14 Richard Ross Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172165A1 (en) * 2008-02-19 2011-07-14 Peter Artymiuk Modified linkers
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670147B1 (en) * 1997-01-16 2003-12-30 Aventis Pharma Deutschland Gmbh Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
US20040033511A1 (en) * 2000-09-15 2004-02-19 Klaus Pfizenmaier Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines)
US20020151478A1 (en) * 2001-01-09 2002-10-17 Yuti Chernajovsky Latent fusion protein
US20050214762A1 (en) * 2002-01-25 2005-09-29 Asterion Limited Polypeptide variants
US20040259768A1 (en) * 2002-09-03 2004-12-23 Vit Lauermann Targeted release
US20060205926A1 (en) * 2003-04-09 2006-09-14 Richard Ross Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol

Also Published As

Publication number Publication date
US8734774B2 (en) 2014-05-27
US20130089516A1 (en) 2013-04-11
EP2553101A4 (en) 2013-09-04
EP2553101A2 (en) 2013-02-06
WO2011123683A2 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
WO2011123683A3 (en) Protease activated cytokines
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
WO2013116778A3 (en) Adenoviruses expressing heterologous tumor-associated antigens
MY181199A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
DK3791896T3 (en) COMBINATION THERAPY WITH ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
EP2249861A4 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2013006544A8 (en) Methods for making multimeric polypeptides
WO2010020766A3 (en) Interleukin fusion polypeptides
PL3536703T3 (en) Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
NZ776770A (en) Adam6 mice
WO2013009627A3 (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
MX2012007710A (en) Alpha-amylases.
IN2014DN08695A (en)
WO2014011901A3 (en) Methods and compositions for delivery of biologics
WO2010102052A3 (en) Methods of inhibiting photoreceptor apoptosis
WO2012027558A3 (en) OPTIMIZED miRNA CONSTRUCTS
WO2014058866A3 (en) Treatment of amyotrophic lateral sclerosis
EP3023434A4 (en) Polypeptide, dna molecule encoding the polypeptide, vector, preparation method and use
LT2513306T (en) C. histolyticum recombinant collagenases and method for the manufacture thereof
IL225461A0 (en) Anti-human ccr7 antibodies, nucleic acids encoding the same and compositions comprising the same
WO2012125946A3 (en) Multi-segmented inflatable brachytherapy devices, systems and methods of using the same
WO2012064743A3 (en) Methods for improving heart function
WO2013040517A3 (en) IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH
HK1200867A1 (en) Codon optimized encoding nucleotide sequences of mg53 protein, recombinants and application thereof mg53
EP3049512A4 (en) E. coli separatome-based protein expression and purification platform

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11763460

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011763460

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13639006

Country of ref document: US